Tandem Diabetes Care, Inc.
TNDMHealthcareNASDAQMedical Devices
Scan Results
Daily timeframeTandem Diabetes Care, Inc. designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The $1.21B market capitalization puts TNDM squarely in small-cap range for its industry. It's flagship products are the t:slim X2 insulin delivery system; and Tandem Mobi insulin pump, an automated insulin delivery system.
Market Cap
$1.21B
Beta
1.66
P/E (TTM)
—
P/E (Fwd)
109.65
EPS (TTM)
$-0.91
EPS (Fwd)
$0.16
ROE
-48.0%
ROA
-2.6%
Cash
$456.0M
Total Debt
$739.3M
Free CF
-$43.9M
52W Change
16.7%
Annual Financials
Cash vs Debt
Where TNDM stands vs its 150-day and 200-day moving averages
As of the October 7, 2026 close, TNDM finished 13.44% below its 150-day moving average ($18.67) and 16.62% below its 200-day moving average ($19.38). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is TNDM overbought or oversold?
At the October 7, 2026 close, TNDM's RSI(14) was 38.6, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
Tandem Diabetes Care, Inc. carries $739.3M in total debt against $456.0M in cash reserves — debt is roughly 1.6x the cash position. Managing this leverage effectively will be important for long-term financial stability. Free cash flow is running at -$43.9M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. ROE of -48.0% points to negative capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. Revenue has grown from $801.2M (2022) to $1.01B (2025), reflecting a 27% increase over the period.
Tandem Diabetes Care, Inc.'s elevated beta suggests the stock experiences more pronounced price movements than the overall market, which increases both upside potential and downside risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Tandem Diabetes Care, Inc.'s trajectory.